{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"312.25","upperLimit":"382.76","value":"345.7"},{"comment":"The confidence interval could not be calculated as only 1 patient had an anti-body response above the lower limit of quantitation.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"388.0"}]}],"title":"Pre-vaccination"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"461.54","upperLimit":"630.61","value":"539.5"},{"groupId":"OG001","lowerLimit":"1065.15","upperLimit":"2360.17","value":"1585.5"}]}],"title":"4 weeks post-vaccination"}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"description":"Anti-keyhole limpet hemocyanin antibody was measured immediately prior to and 4 weeks after the first administration of keyhole limpet hemocyanin. The keyhole limpet hemocyanin antibody ELISA assay used keyhole limpet hemocyanin as the plate coat and anti-human IgG-horseradish peroxidase for detection.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received 2 intravenous infusions of rituximab 1000 mg, 14 days apart + methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG000","title":"Rituximab + Methotrexate (Group A)"},{"description":"Patients received methotrexate 10-25 mg/wk orally or subcutaneously during the Treatment Period.","id":"OG001","title":"Methotrexate (Group B)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Immune response per-protocol population: Group A - All patients randomized to Group A who received any rituximab infusion and any vaccine and had pre-vaccination and 4-week post-vaccination blood samples. Group B - All patients randomized to Group B who received any vaccine and had pre-vaccination and 4-week post-vaccination blood samples.","reportingStatus":"POSTED","timeFrame":"Week 32 to Week 36 for Group A and Week 8 to Week 12 for Group B","title":"Serum Level of Anti-keyhole Limpet Hemocyanin Antibody Measured Immediately Prior to and 4 Weeks After the First Administration of Keyhole Limpet Hemocyanin","type":"SECONDARY","unitOfMeasure":"IU/mL"}